ERBB2 and urothelial carcinoma: Differences in gene expression and mutational profile were also seen in urothelial carcinoma, which is characterized by overexpression of EGFR and ERBB2 in approximately 70% and 60% of the tumors, respectively, and clinical response to EGFR/ERBB2 inhibitors.